Objectives: To investigate paraoxonase-1 (PON 1 ) lactonase activity, myeloperoxidase (MPO) activity (as a marker of inflammation) and antioxidant status in plasma of patients with type 1 diabetes mellitus. Methods: Whole blood and plasma samples were collected from patients with diabetes and healthy control subjects. PON 1 lactonase and MPO activities and total antioxidant capacity (TEAC) were determined in plasma. Glycosylated haemoglobin (HbA1c) was quantified in whole blood. Results: Plasma PON 1 lactonase and MPO activities were significantly higher and TEAC was significantly lower in patients with diabetes (n ¼ 18) compared with healthy control subjects (n ¼ 20). There were significant positive correlations between PON 1 lactonase activity and MPO activity and HbA1c level, and plasma MPO and HbA1c. There were significant negative correlations between PON 1 lactonase activity and TEAC, and MPO activity and TEAC. Conclusions: Increased lactonase activity may inefficiently compensate for the high level of chronic inflammation and low antioxidant capacity in the plasma of patients with type 1 diabetes mellitus.
Introduction
The paraoxonase (PON) family comprises three enzymes (PON 1 , PON 2 and PON 3 ) with structural homology and common antioxidant properties. 1 PON 1 has been widely studied due to its anti-atherogenic function and role in cardiovascular disease. 1 The enzymatic activities of PONs include paraoxonase, arylesterase and lactonase, which catalyse the hydrolysis of organophosphates, aromatic esters and lactones, respectively. 2 Alterations in circulating PONs (for example, the concentration and activity of PON 1 ) have been reported in a variety of diseases involving oxidative stress, including diabetes mellitus. 3 Chronic inflammation is common in patients with type 1 diabetes, 4 manifesting as elevated inflammatory markers, 5 immune activation 6 and oxidative stress. 7, 8 These factors are strongly associated with the initiation and progression of atherosclerosis and cardiovascular disease. 9 Plasma myeloperoxidase (MPO) is a valuable marker of chronic inflammation, endothelial dysfunction and cardiovascular disease. 10 Diabetes is associated with high levels of oxidative stress and damage. 11 Antioxidant systems are major mechanisms for protecting cells from oxidative stress-induced damage, and imbalances in the redox mechanism may contribute to the pathogenesis or complications of diabetes mellitus. 12, 13 There is conflicting information regarding the antioxidant status of patients with diabetes, however. 14, 15 In spite of a lack of information regarding PON 1 lactonase activity in patients with type 1 diabetes, its aryl esterase and paraoxonase activities are known to be decreased. 16, 17 Factors including increased oxidative stress and protein glycation have been found to be at least partially responsible for these changes. 3 The aim of the present study was to investigate PON 1 lactonase activity, plasma MPO (as a marker of inflammation) and antioxidant status of patients with type 1 diabetes.
Patients and methods

Study population
This case-control study recruited sequential patients with type 1 diabetes mellitus (defined according to criteria of the American Diabetes Association 18 ) undergoing treatment at the NC Paulescu National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania, between January 2011 and January 2012. Patients were examined for specific chronic complications of diabetes, including microangiopathy, macroangiopathy and hypertension. Exclusion criteria for all study participants were: acute hyperglycemia crisis; inflammatory or infectious disease; active liver disease; acute vascular disease; current immunosuppressive therapy; and vitamin C or E supplementation. All patients were receiving subcutaneous insulin for glycaemic control, with a target glycosylated haemoglobin (HbA1c) level of <7%. Healthy staff members were recruited as volunteers and included as control subjects. No attempt was made to age-or sex-match the control population.
The study was approved by the ethics committee of the NC Paulescu National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania. Written informed consent was obtained from all study participants.
Plasma preparation
All participants provided peripheral blood samples after an overnight fast. Blood (5 ml) was collected into sterile tubes containing 34 IU lithium heparin and centrifuged at 548 Â g for 15 min at 4 C. The resulting plasma was placed on ice prior to storage at À80 C until further analysis. Plasma was used for the assay of PON 1 , MPO and total antioxidant activity. HbA1c was quantified in whole blood (2 ml) collected into sterile tubes containing potassium-EDTA (1.2-2.0 mg EDTA/ml of blood).
Sample analysis
All assays were performed on a Perkin-Elmer Lambda EZ 210 spectrophotometer (Perkin-Elmer, Boston, MA, USA), and were carried out on duplicate samples.
Total protein was assayed via the Bradford method (Bio-Rad Laboratories, Hercules, CA, USA). Optical density was measured at 595 nm against a bovine serum albumin standard curve.
Plasma PON 1 lactonase activity was determined using dihydrocoumarin (DEPCyMC;
Sigma-Aldrich Chemie, Steinheim, Germany), as described previously, 19 with absorbance measured at 270 nm. Enzymatic activity was expressed as U/ml.
MPO activity was determined with the o-dianisidine-hydrogen peroxide method. 20 The change in absorbance was measured at 460 nm (" 11 300/mol per cm) for 5 min. Results were expressed as units of MPO/ mg protein, with 1 unit of MPO defined as the quantity of enzyme degrading 1 nmol hydrogen peroxide/min at 25 C.
Total antioxidant activity was determined using the 6-hydroxy-2,5,7,8-tetramethylchroman-2 carboxylic acid (Trolox) equivalent antioxidant capacity (TEAC) assay developed by Miller et al, 21 with modifications. 22 Optical density (absorbance) was read at 734 nm against 5 mmol/l phosphate-buffered saline (pH 7.4). The percentage inhibition of absorbance (directly proportional to antioxidant activity) was calculated. The assay was calibrated against a Trolox standard curve. Plasma TEAC was expressed as mmol of Trolox equivalent per litre of plasma.
Whole blood HbA1c was quantified by standardized immunoturbidimetry (Cobas Integra Õ ; Roche Diagnostics, Mannheim, Germany) in accordance with the manufacturer's instructions. 23 
Statistical analyses
Data were presented as adjusted predictive values based on a linear regression model, using age as the independent variable. No data imputations were performed. The data were, therefore, corrected for age as a potential confounder. Between-group differences were determined using parametric (two-tailed Student's t-test) or nonparametric (two-tailed Wilcoxon) tests. The strength of association between pairs of variables was assessed using Spearman rank correlation analysis. Data analyses were performed using InStat version 3 (GraphPad Software; La Jolla, CA, USA). P-values <0.05 were considered statistically significant.
Results
The study included 18 patients with diabetes (7 male/11 female; mean age 42.4 AE 3.1 years; age range 18-59 years) and 20 healthy control subjects (13 male/7 female; mean age 24.7 AE 1.3 years; age range 17-41 years). The demographic and clinical characteristics of the participants are shown in Table 1 . Patients were significantly older and had significantly higher HbA1c than controls (P < 0.001 for both comparisons).
Data regarding plasma antioxidant capacity and enzyme activities are shown in Table 2 . PON 1 lactonase and MPO activities were significantly higher and plasma TEAC was significantly lower in patients than in controls (P < 0.001 for each comparison).
In the patient group, there were significant positive correlations between PON 1 lactonase activity and MPO activity (r ¼ 0.997, P < 0.0001) and HbA1c level (r ¼ 0.983, P < 0.0001), and MPO activity and HbA1c (r ¼ 0.982, P < 0.0001). There were significant negative correlations between PON 1 lactonase activity and TEAC (r ¼ À0.968, P < 0.0001), and MPO activity and TEAC (r ¼ À0.996, P < 0.0001).
Discussion
The present study identified increased levels of PON 1 lactonase activity and decreased total antioxidant capacity in the plasma of patients with type 1 diabetes mellitus compared with healthy control subjects. The TEAC assay is a validated, standardized method for determining total antioxidant capacity of a biological sample. 24 Our data, therefore, suggest defective antioxidant function in type 1 diabetes despite apparent upregulation of PON 1 lactonase. It is possible that this may be due to the known decrease in activity of PON 1 when dissociated from high-density lipoprotein (HDL) to the lipoprotein-free serum fraction under diabetic conditions. 25 It has been shown that the higher the concentration of glucose in plasma from patients with diabetes, the higher the rate of PON 1 dissociation from HDL. 26 In vitro studies have found that that various oxidative stress systems differentially impair PON 1 activities, 27 and that HDL-bound PON 1 lactonase is less sensitive than HDL-bound PON 1 arylesterase in the same specific oxidative environment. 27 Similar data have been found in patients with type 2 diabetes. 28 PON 1 lactonase activity has also been shown to decrease with higher carotid intima-media thickness, suggesting that this enzyme is an independent risk factor for atherosclerosis in patients with diabetes. 28 Substrate availability may also influence PON 1 lactonase activity in diabetes. 29 Homocysteine and homocysteine-thiolactone are natural substrates of PON 1 lactonase, 30 and high homocysteine concentrations are an independent risk factor for cardiovascular disease. 31 Homocysteine-thiolactone is a naturally occurring metabolite of homocysteine in all human cells, and may be responsible for its deleterious effects. 32 Clinical studies have indicated that PON 1 lactonase activity and homocysteine levels vary in diabetes and some metabolic diseases. 33 Plasma MPO activity was also increased in plasma from patients with diabetes compared with control subjects in the present study, and MPO activity was positively correlated with HbA1c. This suggests that diabetes is characterized by chronic inflammation, in accordance with data showing the importance of plasma MPO concentration and chronic inflammation as predictors for atherosclerosis progression in coronary disease. 34, 35 Studies have found that MPO activity is a source of reactive oxygen species (ROS), 36 amplifying the ROS-induced impairment of endothelium-dependent relaxation via reduction of nitric oxide bioavailability. 37 Furthermore, MPO is a well established inflammatory marker related to endothelial dysfunction and coronary disease, 10 and ROS are considered to be mediators of chronic inflammation in diabetes. 38 PON 1 lactonase reduces lipid peroxides and exhibits peroxidase-like activity. 39 The positive correlation between PON 1 lactonase activity, MPO activity and HbA1c in our patients with type 1 diabetes therefore suggests a protective role of PON 1 in the development of atherosclerosis, in accordance with data indicating a role for PON 1 in the prevention of atherosclerosis and cardiovascular disease. 40 It could be speculated that the increased peroxidase-like activity of PON 1 lactonase may reflect a compensatory response against ROS overproduction generated by MPO activity.
There are several limitations of our study. The incomplete evaluation of all activities of PON 1 results in limited characterization of PON 1 function in type 1 diabetes. The quantification of homocysteine or homocysteine-thiolactone would allow better characterization of PON 1 lactonase activity or other activities, such as arylesterase. Isolation of serum lipoproteins would permit analysis of serum PON 1 distribution between HDL and lipoprotein-deficient serum, and the comparison of PON 1 biological functions in these fractions. This study was also limited by its small sample size, although this is more likely to bias the results toward a negative finding (due to insufficient statistical power) than a falsepositive result.
In conclusion, our study suggests that increased lactonase activity may inefficiently compensate for the high level of chronic inflammation and low antioxidant capacity in the plasma of patients with type 1 diabetes mellitus. This observation underlies the antioxidant properties described previously in relation to the lactonase activity of PON 1 .
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